Summary.-One hundred and seven untreated patients with acute myelogenous leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October 1970 and 31 January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment-a group to receive chemotherapy alone and a group to receive the same chemotherapy with immunotherapy. The patients were then given induction chemotherapy and 45 of them attained complete remission. All patients in remission then received chemotherapy consisting of 5 days treatment every 28 days. Patients receiving immunotherapy were also given multiple weekly intradermal injections of irradiated stored AML cells and Glaxo B.C.G. using a Heaf gun. There were 19 patients in the group which received only chemotherapy during remission; 7 of these patients remain alive (median survival after attaining remission 303 days) and only 5 are still in their first remission (median remission length 188 days). Twenty-three patients were allocated to receive immunotherapy during remission in addition to chemotherapy and 16 remain alive (median 545 days) and 8 are in their first remission (median 312 days). The difference in survival of the two groups is significant with a P value of 0 003. FOLLOWING recent improvements in chemotherapy, approximately half of all patients with acute myelogenous leukaemia (AML) achieve complete remission (Crowther et al., 1970; Crowther et al., 1973) but chemotherapy alone has proved disappointing for maintaining these remissions (Clarkson, 1972; Whitecar et al., 1972; Crowther et al., 1973) . This study was undertaken to see if remission length and survival could be increased when immunotherapy was included as part of the remission treatment. In a clinical study of patients with AML, chemotherapy alone during remission has been compared with chemotherapy plus immunotherapy. The maintenance chemotherapy was chosen to avoid immunosuppression as far as possible. tory studies showed (vide infra) that this could be achieved by giving the cytotoxic drugs in widely spaced courses of short duration and by avoiding the use of powerfully immunosuppressive agents such as cyclophosphamide. The immunotherapy given was irradiated allogeneic stored myeloblastic leukaemia cells and B.C.G.; the reason for choosing this combination for immunotherapy and the doses and timing employed are outlined below.
Scientific basis for the immunotherapy regitme
Attempts to influence the course of cancer in man by a variety of different immunological manoeuvres have been reported for more than 80 years (see review by Currie, 1972) . To show that these procedures are clinically useful requires comparative studies and up till now only 4 have been reported, 3 of acute lymphoblastic leukaemia (Mathe, 1969; Medical Research Council Childhood Leukaemia Study Group Report, 1971 ; Leukaemia Study Group A (U.S.), 1973), and the fourth in patients with gliomata (Bloom et al., 1973) .
The immunotherapy regimen described here is based on results obtained from animal experiments and from clinical studies in which changes in the immunological responses of patients with acute leukaemia were measured after auto-immunization With irradiated leukaemia cells.
An ahti-tumour action of injected irradiated tumour cells in animals was demonstrated by Haddow and Alexander in 1964 , who found that the rate of recurrence of primary chemically induced sarcomata in rats following limited local radiotherapy was reduced by the injection of autologous tumour tissue obtained by biopsy and rendered non-viable by irradiation in vitro. In the absence of local irradiation of the tumour, the immunotherapy was ineffective because the host's immune reaction can kill only a small number of residual tumour cells even after stimulation. Later studies (Alexander et al., 1967) showed that autoimmunization overcame an immunological defect in the tumour bearing rat. The immune responses against primary sarcomata in unimmunized rats is impaired because the lymph nodes draining the tumour are paralysed by antigen overload. However, a powerful systemic immune response can be generated in tumour bearing rats by inoculation of irradiated tumour cells, at sites distant from the tumour, since lymph nodes that are not paralysed are stimulated in this way.
The response seen in rats with primary sarcomata prompted a clinical trial in 1964 of patients with glioma muLltiformae, but no benefit was obtained from giving irradiated autologous tumour following surgery and radiotherapy (Bloom et at., 1973) . We now think that the reasons for this failure were the anatomical inaccessibility of the tumour and insufficient immunization.
Quantity and frequency of treatment.-In studies on patients with disseminated melanoma immunization with irradiated tumour cells induced the appearance of antibodies directed against the tumour but this phenomenon was only seen after more than 5 x 108 irradiated tumour cells had been injected (Ikonopisov et al., 1970) . The effect was only transient and the antibodies d(lisappeared within 2 weeks of autoimmunization. The same effect could be obtained repeatedly when sufficient tumour was available for further immunizations. Autoimmunization with similar quantities of tumour also temporarily increased the specific cytotoxicity of the mononuclear cells in the blood of these patients (Currie, Lejeune and Hamilton Fairley, 1971; Currie and Basham, 1972) .
Before the present leukaemia trial was started, we determined the response of leukaemia patients in remission to immunization with irradiated leukaemia cells (Powles et al., 1971 (Powles and Grant, 1973) . We decided that a total of 1 x 109 irradiated leukaemia cells should be administered weekly at multiple subcutaneous states.
The reasons for using allogeneic cells. The leukaemia cells used for immunization were obtained from other patients with the same disease (i.e. allogeneic). Using the patient's own stored cells would have severely limited the number of patients who could enter the trial, since less than a quarter of presenting patients had enough circulating leukaemia cells, or were well enough to make collection with the I.B.M. machine feasible. Animal experiments had already shown that the production of both antibodies (Gorer and Amos, 1956 ) and cytotoxic lymphocytes (Alexander and Hall, 1970) directed against weak tumour antigens was more effective following immunization with allogeneic than with syngeneic tumour cells. The use of allogeneic leukaemia cells in man constituted a calculated risk since the evidence that leukaemia associated antigen(s) is common to all patients is tenuous. The technique of mixed cell cultures which demonstrated the presence of a specific antigen on acute leukaemia cells (Fridman and Kourilsky, 1969; A?iza et al., 1969; Powles et al., 1971; Gutterman et al., 1972) , cannot provide information about cross reactivity. But the serum of patients with leukaemia frequently contains factors which alter the reactivity of these mixed cell cultures Gutterman et al., 1973) and in some instances we have found these factors specifically inhibit leukaemia cell recognition with cross reactivity between patients (unpublished). Herberman (1973) found that delayed hypersensitivity skin reactions could be induced in patients with acute myelogenous leukaemia by extracts of allogeneic AML cells. These data suggest that a membrane antigen may be shared by leukaemia cells taken from different patients. The assumption for a cross reacting antigen in myelogenous leukaemia is strengthened by the demonstration (Hellstr6m et al., 1971; Currie and Basham, 1972) The only clinical evidence that B.C.G. may be useful therapeutically is based on the study by Mathe (1969) for maintaining remission in childhood acute lymphoblastic leukaemia (ALL) using either B.C.G. alone or in conjunction vwith irradiated leukaemia cells.
The reason for selecting acute myelogenous leukaemia.-We decided to conduct our studies in AML, not ALL, because modern chemotherapy is so poor for controlling the former that an answer soon becomes apparent, whereas many years of study are required to obtain significant results in ALL. In addition, patients with AML are adults and so tolerate better painful intradermal injections of cells which we give weekly. More recently we have found (unpublished) that patients with AML might be better suited for immunotherapy than patients with ALL because during remission lymphocytes from patients with AML respond better in the mixed lymphocyte reaction than those of patients with ALL. consisting of 5-day courses of cytosine arabinoside and daunorubicin, alternating with 5 days of cytosine arabinoside and 6-thioguanine. Between every 5 days of treatment there was a 23-day gap and it was during this period that those patients allocated received additional immunotherapy. All patients stopped maintenance chemotherapy after one year (12 courses) and thereafter the immunotherapy patients received only immunotherapy, and the chemotherapy patients received no further treatment. The final allocation of the patients who attained full remission was 19 to chemotherapy only, and 26 patients to chemotherapy plus immunotherapy. These 2 groups did not have equal numbers because they were allocated when they first entered hospital and the number in each group that attained remission was not the same.
The exact time at which immunotherapy started(show-n in . Fig 1) , was whenever possible, just before complete remission, at a time when the marrow was hypoplastic, and in all instances subsequent marrow biopsies confirmed that these patients achieved a full remission.
Of the 26 patients allocated immunotherapy, 3 have not been included in the analysis. One of these patients died of infection after attaining full remission but before immunotherapy was given; the other 2 patients are the most recent entries and we feel have been in remission for too short a period to make analysis meaningful (8 days and 22 days)-see Table I , patients 24, 25 and 26.
Immunotherapy. As soon as the bone marrow became hypoplastic (i.e. just before full remission) all immunotherapy patients received weekly B.C.G. and irradiated allogeneic myeloblastic leukaemia cells. The injections were deliberately timed to avoid the 5-day courses of chemotherapy.
B.C.G.-The B.C.G. given was a freezedried percutaneous preparation obtained from Glaxo and when reconstituted contained 10 mg of organisms per ml, of which approximately 20%0 were viable. Forty needle punctures in the skin to a depth of 2 mm using a Heaf gun gave an approximate dose of 1 x 106 live organisms. All four limbs received the B.C.G. in turn, one weekly.
Cells. The cells used for immunotherapy were irradiated AML cells and were injected into the 3 limbs not receiving the B.C.G. that w-eek. These cells were collected from the peripheral blood of suitable patients with AML using a NCI/IBM cell separator (Buckner et al., 1969) . Useful quantities of cells couldbe obtained from donors with blast counts as low as 1000/mm3 and as many as 1 x 1012 cells could conveniently be collected from a single donor if the white cell count of blood was very high. We have now collected leukaemia cells from 73 patients between the ages of 8 and 73 years and they suffered little discomfort during the 2-5 hours required to remove the cells. The leukaemia cells were collected into 70 ml acid citrate dextrose (Fenwal Formula A) to give a final cell concentration between 2 x 107 and 1 x 109, depending upon the blood count of the patient. The final volume of cells was approximately 500 ml (including the A.C.D.) and the quantity of plasma varied according to the cell concentration. If necessary, the cells were further concentrated using an MSE 6L centrifuge (2000 rev/min) for 15 min so as to give a final concentration of 1 x 109 cells/ml. The red cell concentration varied between 1 x 108/ml and 1 x 109/ ml. The cell suspension was then mixed with an equal volume of culture medium 199 (Wellcome) containing dimethylsulphoxide (DMSO) and dispensed into 2 ml glass ampoules which were heat sealed. The final concentration of DMSO was 10%. The cells were then frozen slowly at 1°/min to -30°C using a Planer Ltd. gas phase programmed freezer and stored in the gas phase liquid nitrogen. When required the cells were thawed rapidly at 37°C, washed and resuspended in medium 199 at 4°C. This process was found to damage only a small fraction of the cells (Powles and Grant, 1973) . The cells were then irradiated at 4°C at a concentration of 1 x 108/ml with 10,000 rad at a rate of 1000 rad/min using a cobalt 60 source, and then immediately injected into the 3 limbs, both intradermally and subcutaneously. Approximately 1 x 109 cells suspended in 6 ml of culture medium were injected each week at 3 sites (i.e. 2 ml into each site). Individual patients received cells from the same donor for as long as possible. These cells were selected for morphological similarity with the recipient's disease, but no attempt was made to match either the red blood cell or transplantation antigens of the donor and the recipient. If patients relapsed the initial induction treatment with daunorubicin and cytosine arabinoside was repeated whenever possible. If no regression of the leukaemia was seen the treatment was usually changed to a combination of cyclophosphamide and 6-thioguanine. If remission occurred then the maintenance treatment was modified to a single injection of daunorubicin and 3 days of cytosine arabinoside, followed 11 days later by 3 days of oral cyclophosphamide and 6-thioguanine. After another 1l-day gap, the whole cycle was repeated with maintenance chemotherapy for 3 days every fortnight. Those patients who previously received immunotherapy were given further treatment with B.C.G. and a different population of irradiated AML cells.
RESULTS
The age, sex, initial blood count and morphological sub-type of the patients studied are shown in Table I . Also included in this table are the remission lengths and survival times of these patients.
Survival time
Twelve of the 19 patients receiving only chemotherapy for the maintenance of remission have died, compared with only 7 of the 23 immunotherapy patients. Fig. 2 shows actuarial analysis of the duration of survival of these patients after remission induction (given in Table  I ) and allows the prediction that the median duration of survival of the chemotherapy group is 303 days and 545 days for the immunotherapy group (in fact, this group of patients has not quite reached the median yet). The mean duration required to obtain remission in these patients is 60 days and this should be added to above figures to obtain overall survival time after diagnosis. Statistical analysis of the survival data (Table II, (1 1) ± Analysis of patients who have been at least 3 months in remission. t Survival calculated from the time they enter complete remission. C Chemotherapy only group; C + I = Chemotherapy plus immonotherapy; N = Number of patients in each group; 0 = Observed number of patients relapsing/deaths; E = Expected number of patients relapsing/deaths, calculated by the " Logrank " non-parametric method (Mantel, 1966; Cox, 1972; Peto and Peto, 1972) ; O/E = Relative relapse rate; P = Statistical significance level of results; R.R. measures the ratio of relative relapse rate in Group C compared with C + I. Brackets: Columns 0 and E = actual number of relapses in immunotherapy group as opposed to the number of relapses that occurred up to the time the last relapse occurred in chemotherapy group. PRAPTr TOIAI r, 9 q SL A difference between the two groups (P -0.003).
Remission length
Fourteen of the 19 patients in the chemotherapy only group have relapsed compared with 15 of the 23 chemotherapy plus immunotherapy patients. Actuarial analysis (Fig. 3) predicts a median remission length for the chemotherapy group of 188 days compared with 312 days for the immunotherapy patients. These remission figures are not as good as we have previously noticed and reported . Analysis of the data in January 1973 (Table II column 1) showed the median remission length of the chemotherapy patients was doubled by the inclusion of immunotherapy from 188 to 375 days (the relative relapse rate of the chemotherapy patients was 2-84 times that of the immunotherapy patients: P -0'02). Analysis of the present data (column 2) shows that the median remission length for the chemotherapy group is unchanged but the median duration for the immunotherapy patients is reduced to 312 days, with a relative relapse rate of only 2-02 times (P = 0.10). The difference between the January and May figures is due to those patients who have entered the trial in the last 6 months and who have been relapsing quickly. This is shown by new analysis of patients admitted up to November 1972 (Table II) which excludes the recent admissions (column 3) or patients relapsing in less than 3 months (column 4) and shows a relative relapse rate, at least 2-65 times greater for the chemotherapy patients (P =0.04). Not only have the remission lengths been short for patients recently admitted to the trial but we have had fewer patients going into complete remission (see page 372). Essentially there is no difference between the proportion of patients relapsing early in the two groups but a significant difference for those still in remission after 120 days (Fig. 3) .
The influence of age on the duration of remission
The age of the patients does not influence the length of remission in this study. The 4 patients over 60 years of age (by chance all allocated to the chemotherapy group) have done well, only one relapsing and dying in less than the expected median for this group (Table I) .
Second remissions
Four of the 15 relapsed patients in the immunotherapy group were reinduced into a full second remission using chemotherapy (Table I ) and then continued on modified chemotherapy plus immunotherapy. In the chemotherapy group only one of the 19 patients in relapse achieved a second remission.
Local effects of immunotherapy
The B.C.G. injections produced an area of erythema which appeared at the site of the needle marks after about 24 hours and became vesicular during the following few days. A crusting lesion about 1 cm across then persisted for about 3 months and usually healed leaving a faint scar. Often the local lymph nodes were enlarged between one and 3 weeks after the injection. During the first 3 weeks after completing induction chemotherapy there was no local reaction to B.C.G. but thereafter all sites, including those previously inoculated, became inflamed. There was no evidence of a systemic effect of B.C.G. in post-mortem studies on 2 patients in this series who had received immunotherapy, although both had been treated for many months.
The injections of allogeneic cells, although painful, produce no local lesions other than an immediate oedematous response and in no instance did we see a delayed type hypersensitivity reaction.
Immune status
After the induction treatment the mixed lymphocyte reaction (MLR) of (FBS) . For mixed lymphocyte reactions 0 5 x 106 stimulating normal allogeneic lymphocytes were treated with 25 mg/ml-' of mitomycin C, washed and suspended in 2 ml medium 199 and 12-5% FBS and added to the reacting lymphocytes. In these conditions the stimulating lymphocytes cannot themselves synthesize DNA. These cell suspensions were then cultured in sealed tubes at 37°C for 6 days. DNA synthesis in the cultured reacting lymphocytes was determined by measuring the incorporation of radioactive thymidine. 15 Ci of [3H] thymidine (specific activity 15 Ci mmol/l) was added and after 60 min at 37°C the cells were extracted by filtration on to a Millipore filter. The cells on the filter were exposed to 10% ice-cold trichloracetic acid, washed with ethanol and radioactivity was determined by liquid scintillation counting. Thymidine incorporation was expressed as ct/min. In cultures in which there was no stimulation (one way autologous mixed lymphocyte reactions) in both normal donors and the AML patients studied, the ct/min was always less than 1000 and so in allogeneic one way MLRs values greater than 1000 were regarded as a significant stimulation. the AML patients was severely depressed. During remission and in spite of receiving intermittent chemotherapy the MLR in these patients becomes steadily more reactive (Table III) . However, a notable feature was that individuals showed marked day-to-day variability in the MLR, particularly following the induction of remission. There was no detectable depression of the MLR as an immediate consequence of the 5-day courses of maintenance chemotherapy.
Studies of the immune status of our immunotherapy patients are to be reported more fully in a later publication, but it is of interest to note that we have seen no consistent alteration in the skin reactivity to B.C.G. or the mixed lymphocyte reaction before relapse in these patients.
DISCUSSION
It is not possible to compare directly the present study with that of Mathe (1969) in ALL since both the disease he treated and the immunotherapy he gave were different. In his study patients received B.C.G., cells, or B.C.G. as well as cells, and after about one year those patients who had received B.C.G. alone began to receive cells. Also, the number of leukaemia cells Mathe gave was 10,000 times less than that used in this study and he used a different strain of B.C.G. Our study shows that immunotherapy, as we give it, has a significant beneficial effect on the duration of remission and the length of survival of patients with AML, but the place of immunotherapy for treating malignant disease must always be considered in the light of the best available conventional methods. The results of two groups of investigators in the United States (Whitecar et al., 1972; Clarkson, 1972) using intensive chemotherapy for treating AML during remission are very encouraging but as yet it is uncertain whether they will be better or worse than our immunotherapy group and so we feel justified in continuing this method of treatment. But patients in our immunotherapy group still relapse and die. Although both remission length and survival are nearly doubled, the likelihood of cure in any but a few of these patients seems remote. To improve these results it is essential to measure the specific host response to immunization in an attempt to develop a rationale for better methods of immunological treatment. It is for this reason that we use leukaemia cells from a single donor instead of using a pool of cells. We can then measure host cell mediated and humoral cytotoxicity directed against both the cells used for immunizing and the patient's own stored leukaemia cells (if available).
